Optimind Pharma Corp. OMND
CNSX
| 02/28/2026 | 11/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -27.05% | 23.86% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -27.05% | 23.86% | |||
| Cost of Revenue | -74.63% | 55.81% | |||
| Gross Profit | 33.03% | -1.80% | |||
| SG&A Expenses | 11.65% | 57.59% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -18.54% | 56.97% | |||
| Operating Income | 3.60% | -195.74% | |||
| Income Before Tax | -177.56% | -159.49% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -177.56% | -159.49% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -177.56% | -159.49% | |||
| EBIT | 3.60% | -195.74% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -200.00% | -100.00% | |||
| Normalized Basic EPS | 0.00% | -- | |||
| EPS Diluted | -200.00% | -100.00% | |||
| Normalized Diluted EPS | 0.00% | -- | |||
| Average Basic Shares Outstanding | 0.01% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.01% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||